FGFR2 and gastric cancer: While most of the studies of multikinase inhibitors were preclinical or single case reports, the phase II GASDOVI-1 trial (NCT01719549) evaluated the safety and efficacy of dovitinib as later line treatment in metastatic GC patients (≥3 line) with FGFR2 amplification, but no results were available despite the end of the trial several years ago.